US Ebola Experiment: An Advancement in Bio-Warfare

As doctors in West Africa skirmish to combat a disease which has claimed more lives than A.L.S. and plane crashes (per year) combined, people are beginning to question why the WHO and U.N. did not contain the Ebola outbreak earlier and why it is spreading at such an unprecedented rate. The demand for San Diego based company Mapp Biopharmaceutical's new wonder drug, ZMapp continues to rise across Western parts of the continent. Despite still being in its testing phases, the WHO has approved the experimental drug for human treatment in West Africa. The result? According to a report released by N.B.C. News two weeks ago, the drug has successfully cured American aid workers Dr Kent Brantly and Nancy Writebol after being infected by the disease in Liberia. What people don't actually know is that, the C.D.C. patented hybrid strains of the Ebola virus on April 29 2010. This gives the C.D.C. and U.S. government exclusive profits and ownership of all Ebola viruses with 70% similarity to the invented Ebola Bundibugyo strain.

Behind the patent lies nine years of research lead by Dr Robert Garry (Professor of Microbiology and Immunology; researcher for BioFactura) and the Tulane University, along side Bio-Warfare researchers from the U.S. Department of Defense - specifically the U.S. Army Research Institute of Infectious Diseases (USAMRIID) from Fort Detrick, Maryland. It is not exactly clear why research on Ebola (Lassa fever) and bio-warfare was conducted in the region years leading to the incident, however, on the 23rd of July 2014 Sierra Leone's Ministry of Health and Sanitation announced that the "Tulane University is to stop Ebola testing during the current outbreak."

The Liberian Daily Observer published an article last week Tuesday by former Professor of Plant Pathology, Dr Cyril E. Broderick claiming that "testing has been secretly taking place in Africa". Global Biodefence, a website aimed at informing the world about the latest health threats such as Lassa fever, confirmed that USAMRIID has been operating in the region since 2006. USAMRIID opened the doors for the Defense Threat Reduction Agency (DTRA) to operate in the area with USAMRIID and the bright minded researchers of Tulane University. It's no secret that DTRA is a major researcher of bio-warfare and W.M.Ds on a global scale.

Recently, Monsanto has decided to fund Tekmira Pharmaceuticals $1.5million towards research on an anti-Ebola drug. This wouldn't be the first time Tekmira received 'generous' cash advances. In the past, Tekmira received $140million from the U.S. Department of Defense, long before the outbreak.

According to the Centre for Research Globalization, US Ebola researchers from Tulane University have been kicked out of Sierra Leone, along with bio-warfare researchers from USAMRIID. The Sierra Leone government ordered a U.S. bio-weapons lab in Kenema to be moved, following claims that the U.S. State Department may have something to do with the outbreak. In effect, the Sierra Leone government has requested the C.D.C.'s 'bio-war' lab results for analysis.

"Usually the process of getting a drug approved for use takes years," Clinical Research Associate, Stacey Treu on the ZMapp trial process. "First, they need to test it on healthy humans to check for major side effects. After that, testing begins on a population of diseased individuals, followed by a much larger population when there's progress. These trials can take months, even years. On the other hand, there maybe an expedited process for outbreaks, that I am unaware of although it's unlikely."

It seems that the U.S. State Department has a lot to answer for. For instance, why did the C.D.C. monopolize all profits relating to Ebola (Lassa fever) four years prior to the outbreak?

-Nick Ndaba

[image sources: -media.worldbulletin.net
-emptywheel.net
-NBC News
-Louisiana Record
- IBTimes]